New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ethinylestradiol 0.035mg (does not include an overage of aprox. 3%);  ; norethisterone 0.5mg;  ;   - tablet - active: ethinylestradiol 0.035mg (does not include an overage of aprox. 3%)   norethisterone 0.5mg     excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone lactose lactose monohydrate magnesium stearate microcrystalline cellulose sunset yellow fcf as fd&c yellow lake - contraception.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 150 mg/ml - injection (depot) - 150 mg/ml - active: medroxyprogesterone acetate 150 mg/ml excipient: hydrochloric acid macrogol 3350 methyl hydroxybenzoate polysorbate 80 propyl hydroxybenzoate sodium chloride sodium hydroxide - adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - inotuzumab ozogamicin 1mg - powder for injection - 1 mg - active: inotuzumab ozogamicin 1mg excipient: polysorbate 80 sodium chloride sucrose trometamol - besponsa is indicated for the treatment of adults with relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukaemia (all).

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pneumococcal polysaccharide serotype 1 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 14 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 18c 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 19a 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 19f 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 23f 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 3 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 4 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 5 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 6a 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 6b 4.4ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 7f 2.2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 9v 2.2ug (conjugated with diphtheria crm 197 protein) - suspension for injection - 0.5 ml - active: pneumococcal polysaccharide serotype 1 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 14 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 18c 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 19a 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 19f 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 23f 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 3 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 4 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 5 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 6a 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 6b 4.4ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 7f 2.2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 9v 2.2ug (conjugated with diphtheria crm 197 protein) excipient: aluminium phosphate polysorbate 80 sodium chloride succinic acid water for injection - active immunisation for the prevention of pneumococcal disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f in adults and children aged more than 6 weeks of age. the use of prevenar 13 should be guided by official recommendations.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 25mg - powder for injection with diluent - 25 mg - active: etanercept 25mg excipient: mannitol nitrogen sucrose trometamol water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 50mg;   - powder for injection with diluent - 50 mg - active: etanercept 50mg   excipient: mannitol nitrogen sucrose trometamol water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 100mg - capsule - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide gelatin   iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide   - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 125mg - capsule - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide gelatin   iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide   - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 75mg - capsule - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide gelatin   iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate microcrystalline cellulose opacode white s-1-7085 sodium starch glycolate titanium dioxide   - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ziprasidone hydrochloride monohydrate 113.25mg equivalent to 100 mg ziprasidone - capsule - 100 mg - active: ziprasidone hydrochloride monohydrate 113.25mg equivalent to 100 mg ziprasidone excipient: lactose monohydrate magnesium stearate pregelatinised maize starch - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.